Viveve to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 11, 2022

Rhea-AI Summary

Viveve Medical (NASDAQ:VIVE) will report its second quarter 2022 financial results and provide a corporate update on August 11, 2022, after U.S. market close. A conference call is scheduled for 5:00 PM ET, accessible via phone or live webcast. Viveve specializes in women's health, particularly in treating stress urinary incontinence (SUI) with its Viveve® System, cleared by the FDA for various surgical procedures. The company's ongoing clinical trial, PURSUIT, aims to improve SUI outcomes, with topline results expected by the end of 2022.

Positive

• FDA clearance of the Viveve System for general surgical procedures.
• Ongoing clinical development program for stress urinary incontinence with PURSUIT trial results expected by end of 2022, potentially supporting a new SUI indication.

Negative

• None.

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.

The second quarter 2022 results conference call may be accessed on Thursday, August 11^th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/webcast.html?webcastid=edZnKiaV. Participants may also register for the conference call at https://dpregister.com/sreg/10166270/f3a2e624b3.

A recording of the webcast will be posted on the Company's investor relations website following the call at ir.viveve.com and will be available online for 90 days.

About Viveve

Viveve Medical, Inc. is a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI). Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates Cryogen-cooled Monopolar Radiofrequency technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. In the United States, the Viveve® System is cleared by the Food and Drug Administration (FDA) for use in general surgical procedures for electrocoagulation and hemostasis. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in 50 countries.

Viveve continues to advance its clinical development program in SUI. Viveve received FDA approval of its Investigational Device Exemption (IDE) application to conduct the multicenter, randomized, double-blinded, sham-controlled PURSUIT trial for improvement of SUI in women in July 2020 and FDA approval of its requested amendments to the IDE protocol in December 2020. Initiation of the trial was reported in January 2021 and completion of subject enrollment was announced on December 14, 2021. Topline results are anticipated at the end of 2022. If positive, results from the PURSUIT trial may support a new SUI indication in the U.S.

For more information visit Viveve's website at https://ir.viveve.com.

Safe Harbor Statement

All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including, without limitation, implied and express statements regarding Viveve Medical, Inc.'s plans, timelines, or presumptions of results for the PURSUIT trial. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the timing, progress and results of our clinical trials, the fluctuation of global economic conditions, the impact of the novel coronavirus termed COVID-19 on our clinical development and regulatory review and clearances and on the manufacturing, placements and patient utilization of our Viveve Systems, the performance of management and our employees, our ability to obtain financing, our evaluation of strategic alternatives, our ability to obtain approval or clearance for sale of our medical device for all indications sought, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov. Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware, unless required by law.

Viveve is a registered trademark of Viveve, Inc.

Investor Relations contacts:
Amato and Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com

Media contact:
Bill Berry
Berry & Company Public Relations
(212) 253-8881
bberry@berrypr.com

SOURCE: Viveve Medical, Inc.

View source version on accesswire.com:
https://www.accesswire.com/710138/Viveve-to-Report-Second-Quarter-2022-Financial-Results-and-Provide-Corporate-Update-on-August-11-2022

FAQ

When will Viveve Medical report its Q2 2022 financial results?

Viveve Medical will report its Q2 2022 financial results on August 11, 2022.

What is the significance of the PURSUIT trial for Viveve Medical?

The PURSUIT trial aims to improve outcomes for stress urinary incontinence and its positive results may support a new indication in the U.S.

How can I access Viveve Medical's Q2 2022 earnings call?

The earnings call can be accessed by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast on their investor site.

What technology does the Viveve System utilize?

The Viveve System uses Cryogen-cooled Monopolar Radiofrequency technology for treatments.

What approvals has the Viveve System received?

The Viveve System has received FDA clearance for general surgical procedures and additional international approvals for vaginal laxity and sexual function.